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Abstract
Purpose: Melatonin has neuroprotective effects in animal studies and has been suggested to decrease adverse reactions of   chemotherapy 
including neuropathy. This pilot trial aimed at assessing whether melatonin, given during taxane chemotherapy for breast cancer, will 
decrease the incidence and/or severity of neuropathy. 
Methods: Twenty two consecutive patients beginning chemotherapy for breast cancer with paclitaxel, or docetaxel were enrolled. 
toxicity assessment per NCI-CTC 3.0 scale and FACT-Taxane quality of life questionnaire. 
Results: Neuropathy was seen in 45% ( n = 10) of patients, 23% (n = 6) grade 1 and 22% (n = 5) Grade 2 neuropathy. No grade 3 
  neuropathies were reported. The majority (55%) of all patients reported no neuropathy. Compliance with melatonin (.60% of dose) 
was seen in most patients (86%) No patient reported daytime sedation. The median FACT-Taxane quality of life end of study score was 
137, with only a 0.5 median decline from baseline. 
Conclusion: Patients receiving melatonin during taxane chemotherapy had a reduced incidence of neuropathy. Melatonin may be   useful 
in the prevention or reduction of taxane-induced neuropathy and in maintaining quality of life. Larger trials are warranted to further 
explore the role of melatonin in neuropathy treatment and prevention.
Keywords: neuropathy, taxane, melatonin, quality of life
Patients received melatonin 21 mg daily at bedtime. Incidence and severity of neuropathy were assessed using neurological   examinations, Nahleh et al
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Introduction
Taxane-related  neuropathy  remains  a    challenging 
  clinical  problem  causing  treatment  delays  and 
  worsening of quality of life. Taxane-based cytotoxic 
chemotherapeutic agents are among the most potent 
agents for the treatment of a variety of types of can-
cers  including  breast,  lung,  and  ovarian  cancers.1,2 
Taxanes are standard components of many   therapeutic 
  regimens in both early stage and metastatic breast 
cancer.  These  medications,  by  inhibiting  microtu-
bules, are known to cause neurotoxicity which can 
decrease the quality of life in many patients and may 
necessitate discontinuation of chemotherapy.3–7
The high incidence of toxic neuropathy is a sig-
nificant limiting factor in patients receiving taxanes. 
Agents that could reduce the incidence or severity of 
taxane  related  neurotoxicities  are  urgently  needed. 
Multiple medications have been evaluated for that 
purpose.8,10,11 However, no therapy has been consis-
tently  successful  and  there  is  no  current  approved 
medication  to  prevent  neuropathy  or  decrease  its 
severity in this setting.
Melatonin, a pineal hormone has been suggested to 
exert a neuroprotective effect in preclinical and   clinical 
studies.12–15 At this time it is not clear if   melatonin is 
effective in the reduction of the   incidence or severity 
of taxane-induced neuropathy. In this study, we aim 
to assess the effect of melatonin on taxane-induced 
neuropathy  in  consecutive  patients  diagnosed  with 
breast cancer at a single University affiliated cancer. 
We plan to   determine whether melatonin given during 
taxane chemotherapy may decrease the incidence of 
neuropathy.
patients and Methods
Design
This is an open label, phase II pilot study using mela-
tonin to evaluate its effect on preventing neuropathy or 
decreasing its severity in breast cancer patients initiating 
taxane chemotherapy with standard paclitaxel, albumin 
bound paclitaxel, or docetaxel. The study was approved 
by the local review board and each patient signed an 
informed consent form prior to her enrolment.
patients’ demographics and study 
characteristics
Women with biopsy-proven breast cancer were recruited 
from  three  breast  oncology  clinics  at  a  University 
affiliated  cancer  center  after  being  scheduled  for 
treatment with paclitaxel,   nab-paclitaxel, or docetaxel 
for early stage or advanced breast   cancer. Patients 
with  known  preexisting  neuropathy,  or    history  of 
exposure to drugs known to cause   neuropathy includ-
ing taxanes were excluded. No concurrent treatment 
with other therapy for neuropathy was allowed dur-
ing protocol treatment. Twelve patients (54%) have 
received  previous  non-  taxane  chemotherapy.  The 
treatments received were as follows: twenty (90%) 
patients received paclitaxel with a median dose of 
750 mg/m2 delivered (range 450–1350 mg/m2). The 
majority  (54%)  received  paclitaxel  on  a  weekly 
schedule and 36% on an every 2 or 3weeks schedule. 
Two patients (9%) received docetaxel at the standard 
dose of 75 mg/m2 given every 3 weeks for 6 doses. 
The median length of taxane treatment was 52.5 days 
(range  21–105  days).  Patients  with  nonmetastatic 
breast cancer received surgery and radiation therapy 
per standard clinical practices.
On the first day of chemotherapy every participant 
received one batch containing a supply of melatonin 
3 mg tablets for 28 days. Participants were asked to take 
7 tablets (21 mg) daily at bedtime. Patients were asked 
to return their bottles of melatonin to assess compliance 
every 28 days. Melatonin was given for the duration of 
taxane chemotherapy in the adjuvant, neoadjuvant set-
ting or metastatic setting. Once taxane chemotherapy 
was discontinued, patients continued to take melatonin 
for an additional 28 days. Final evaluation was done 28 
days after discontinuation of taxane or 6 months after 
initiation of melatonin if the patient continues taxane 
chemotherapy for longer than 6 months.
evaluation of neurotoxicity
Prior to the initiation of the first chemotherapeutic 
cycle, each participant underwent a complete neuro-
logical examination and a neuropathy evaluation per 
National Cancer Institute’s Common Toxicity Crite-
ria (NCI-CTC) 3.0 scale. According to the NCI-CTC, 
peripheral neuropathy may be graded on a scale of 
1 to 5.17 A grade of 1 indicates asymptomatic che-
motherapy  induced  peripheral  neuropathy  (CIPN), 
2 indicates symptomatic CIPN, 3 denotes CIPN that 
interferes  with  activities  of  daily  living  (ADL),  4 
signifies disabling CIPN, and 5 indicates death. The 
patients also completed a Functional Assessment of 
Chronic Illness Therapy (FACT) -Taxane quality Melatonin for taxane-related neuropathy
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Table 1. FACT-Taxane (Version 4): detailed questionnaire and scoring system. Below is a list of statements that other 
people with your illness have said are important. please circle or mark one number per line to indicate your response 
as it applies to the past 7 days.
not 
at all
A little 
bit
some- 
what
Quite 
a bit
Very 
much
physical well-being
Gp1 I have a lack of energy 0 1 2 3 4
Gp2 I have nausea 0 1 2 3 4
Gp3 Because of my physical condition, I have trouble 
meeting the needs of my family
0 1 2 3 4
Gp4 I have pain 0 1 2 3 4
Gp5 I am bothered by side effects of treatment 0 1 2 3 4
Gp6 I feel ill 0 1 2 3 4
Gp7 I am forced to spend time in bed 0 1 2 3 4
social/family well-being
GS1 I feel close to my friends 0 1 2 3 4
GS2 I get emotional support from my family 0 1 2 3 4
GS3 I get support from my friends 0 1 2 3 4
GS4 My family has accepted my illness 0 1 2 3 4
GS5 I am satisfied with family communication about my illness 0 1 2 3 4
GS6 I feel close to my partner (or the person who is my main 
support)
0 1 2 3 4
Q1 regardless of your current level of sexual activity, 
please answer the following question. If you prefer not to 
answer it, please mark this box and go to the next section
GS7 I am satisfied with my sex life 0 1 2 3 4
emotional well-being
Ge1 I feel sad 0 1 2 3 4
Ge2 I am satisfied with how I am coping with my illness 0 1 2 3 4
Ge3 I am losing hope in the fight against my illness 0 1 2 3 4
Ge4 I feel nervous 0 1 2 3 4
Ge5 I worry about dying 0 1 2 3 4
Ge6 I worry that my condition will get worse 0 1 2 3 4
Functional well-being
GF1 I am able to work (include work at home) 0 1 2 3 4
GF2 My work (include work at home) is fulfilling 0 1 2 3 4
GF3 I am able to enjoy life 0 1 2 3 4
GF4 I have accepted my illness 0 1 2 3 4
GF5 I am sleeping well 0 1 2 3 4
GF6 I am enjoying the things I usually do for fun 0 1 2 3 4
GF7 I am content with the quality of my life right now 0 1 2 3 4
Additional concerns
NTX1 I have numbness or tingling in my hands 0 1 2 3 4
NTX2 I have numbness or tingling in my feet 0 1 2 3 4
NTX3 I feel discomfort in my hands 0 1 2 3 4
NTX4 I feel discomfort in my feet 0 1 2 3 4
NTX5 I have joint pain or muscle cramps 0 1 2 3 4
hI12 I feel weak all over 0 1 2 3 4
NTX6 I have trouble hearing 0 1 2 3 4
NTX7 I get a ringing or buzzing in my ears 0 1 2 3 4
NTX8 I have trouble buttoning buttons 0 1 2 3 4
(Continued)Nahleh et al
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of  life  assessment  questionnaire  (Table  1).  The 
  participants were clinically re-evaluated at 28 days 
interval while receiving taxane chemotherapy. They 
underwent complete neurological examinations and 
were assessed per NCI-CTC 3.0 scale for neuropathy 
by answering specific questions regarding the pres-
ence of tingling, numbness, pain, muscle weakness 
and motor activities. Four weeks after completion or 
discontinuation of taxane or 6 months after initiation 
of melatonin (if the patient continues taxane chemo-
therapy for longer than 6 months), they underwent 
a final neurological examination, a final assessment 
of  the  incidence  and  severity  of  neuropathy  using 
the  NCI-CTC  3.0  scale  for  neuropathy,  and  com-
pleted the FACT-Taxane quality of life assessment 
questionnaire.
Statistical design and analysis
The primary objective was to assess taxane-related 
neuropathy (any grade) in patients receiving mela-
tonin  during  taxane  chemotherapy  and  compare  it 
with hitstorical controls. The trial was designed to be 
conducted as a pilot study, intended to detect a trend in 
favor of melatonin supplementation, that would jus-
tify its expansion to a subsequent placebo controlled 
randomized trial. Descriptive statistics are reported. 
The incidence of neuropathy, severity of neuropathy, 
and changes in quality of life were assessed using neu-
rological examinations,   NCI-CTC 3.0 scale for neu-
ropathy, and FACT-Taxane   questionnaire,   conducted 
by  the  treating  oncologists  and  verified  by  the  P.I 
(neurological examinations) and investigators on the 
trial (NCIC-CTC 3.0 scale, and FACT-Taxane ques-
tionnaires).  The  FACT-Taxane  Scoring    Guidelines 
were obtained based on the scoring and administra-
tion procedures outlined in the FACT manual.18
results
Twenty three consecutive patients were recruited; one 
patient declined participation. Twenty—two patients 
were suitable for final analysis as shown in Table 2. 
The mean age was 49 years (range 33–68 years). The 
stages were distributed as follows: Stage IIA: 4 (18%); 
stage IIB: 3 (14%); stage IIIA: 5 (23%); stage IIIB: 
4   (18%); stage IIIC: 2 (9%); and stage IV: 4 (18%). 
Neuropathy (all grade) was seen in 46%( n = 10) of all 
patients (Table 3). No patient developed Grade 3 or 4 
neuropathy per NCI-CTC 3.0; 27% (n = 5) had grade 
1 and 23% (n = 5) had grade 2 neuropathies. Fifty five 
percent of all patients (n = 11) reported no neuropathy 
(Grade 0). Other severe adverse events were reported 
as follows: 3 patients had grade 3 nausea or vomiting, 
and one patient had grade 3 fatigue. Two patients with-
drew from the study due to grade 3 nausea and progres-
sive disease, respectively.   Compliance with melatonin 
(.60% of dose) was seen in the majority of patients 
(86%). Two patients reported nighttime sedation. No 
patient reported daytime sedation.
Table 1. (Continued )
not 
at all
A little 
bit
some- 
what
Quite 
a bit
Very 
much
NTX9 I have trouble feeling the shape of small objects  
when they are in my hand
0 1 2 3 4
An6 I have trouble walking 0 1 2 3 4
Tax1 I feel bloated 0 1 2 3 4
Tax2 My hands are swollen 0 1 2 3 4
Tax3 My legs or feet are swollen 0 1 2 3 4
Tax4 I have pain in my fingertips 0 1 2 3 4
Tax5 I am bothered by the way my hands or nails look                 0 1 2 3 4
Table 2. patient characteristics.
characteristics  Result
No. of patients (%) 22 (100)
Mean age, years 49
race 
White
African American 
Asian
 
20 (90) 
1 (5) 
1 (5)
Stages
II
III 
IV
 
7 (32) 
11 (50) 
4 (18)
Taxane
paclitaxel 
Docetaxel
 
20 (91) 
2 (9)Melatonin for taxane-related neuropathy
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All  patients  completed  baseline  FACT-Taxane 
quality  of  life  questionnaire  but  only  11  patients 
completed the final (post-treatment) one. The median 
baseline score was 137 in the whole group and 137.5 
in those who completed both surveys. The median 
end of study score was 137, with only a 0.5 median 
decline  from  baseline,  indicating  no  significant 
change  in  quality  of  life  overall.  Among  patients 
who  completed  both  questionnaires,  most  patients 
reported  some  symptoms  attributed  to  neuropathy 
like   numbness or tingling in hands or feet, discomfort 
in hands or feet, joint pain or muscle cramps, trouble 
buttoning or feeling the shape of small objects , pain in 
fingertips or walking but less than 40% of all patients 
reported those symptoms as severe (Table 4).
Discussion
Taxane-related  neuropathy  remains  a    challenging 
clinical problem; it occurs 24–72 hours after admin-
istration  of  taxanes,  but  may  occur  at  different 
times   during chemotherapy courses, and it may be 
  irreversible. Patients are at increased risk if they have 
received previous neurotoxic drugs. The mechanism 
of taxane induced neuropathy is thought to be due to 
aggregation of intracellular microtubules in neuronal 
cells. It is also thought that taxanes cause intrinsic 
toxicity and injury to cells. However, the exact mech-
anism of neurotoxicity is not known at this time.1,2 
Types  of  neuropathy  caused  by  taxanes  include 
peripheral  neuropathy,  motor  weakness,  myalgias, 
and   arthralgias. About 60%–90% of patients receiv-
ing  taxanes  develop  mild-moderate  neuropathy3–7 
and a many as 30% of treated patients will develop a 
  disabling sensory neuropathy.5
The reported incidence of neurotoxicity with these 
agents varies depending on patient characteristics, che-
motherapy regimen, dose of chemotherapy, and admin-
istration method. At doses used in patients receiving 
adjuvant  treatment  for  breast  cancer,  up  to  90%  of 
Table 4. FACT-Taxane (Neuropathy-related).
symptom  Final 
n = 11 (100%)
numbness or tingling 
in hands 
Little bit/somewhat (Mild 1/2) 
Quite a bit/very much (Severe 3/4)
 
 
2 (18) 
4 (36)
numbness or tingling in feet 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
2 (7) 
3 (27)
Discomfort in hands 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
0 
5 (46)
Discomfort in feet 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
1 (10) 
4 (36) 
Joint pain or muscle 
cramps 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
 
6 (55) 
1 (10)
Feels weak all over 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
6 (55) 
1 (10)
Trouble hearing 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
1 (10) 
0
Ringing or buzzing in ears 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
4 (36) 
0
Trouble buttoning buttons 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
0 
4 (36)
Trouble feeling shape of 
small objects 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
 
2 ( 18) 
1 (10)
Trouble walking 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
3 (28) 
0
Feel Bloated 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
3 (28) 
1 (10)
Hands are swollen 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
3 (28) 
1 (10)
Legs or feet are swollen 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
2 (8) 
0
Pain in fingertips 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
1 (10) 
0
Bothered by the way hands  
or nails look 
Little bit/somewhat (1/2) 
Quite a bit/very much (3/4)
 
 
4 (36) 
1 (10)
Table 3. Neurotoxicity grading as per NCI-CTC 3.0.
symptom no. of patients 
(%)
Neurotoxicity (any grade) 10 (46)
Grade 1   5 (23)
Grade 2   5 (23)
Grade 3 or more   0 (0)Nahleh et al
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patients receiving paclitaxel experience mild-moder-
ate neurotoxicity, around 20% of whom may require 
chemotherapeutic dose reduction.3,4 As many as 30% 
of  treated  patients  will  develop  a    disabling  sensory 
neuropathy.5 A randomized clinical trial in metastatic 
breast cancer compared docetaxel and paclitaxel. The 
incidence of neuropathy was 64% of 222 in patients 
receiving docetaxel and 59% in those receiving pacli-
taxel.6 In other trial Seventy-one percent of 229 patients 
with metastatic breast cancer receiving   paclitaxel pro-
tein bound as a single agent experienced neuropathy.7
Possible  strategies  to  decrease  the  incidence  of 
neuropathy include avoiding paclitaxel doses greater 
than 200 mg/m2, avoiding cumulative doses greater 
than or equal to 250 mg/m2, and giving taxanes as 
continuous  infusions  over  24  hours.8,9 Addition  of 
medications including glutamine, amitriptyline, gaba-
pentin and acetyl-L-carnitine have been evaluated to 
reduce the incidence of neuropathy.8,10,11 However, no 
therapy has been consistently successful. Melatonin 
decreases  peripheral  nerve  injury  and  motoneuron 
loss on melatonin-treated axotomized rats.12 It was 
suggested that it exerts a neuroprotective effect that 
would  attenuate  the  neuropathological  changes  in 
the vagal ganglia following a severe hypoxic insult.13 
Clinical studies have evaluated the role of melatonin 
for counteracting chemotherapy-toxicity, particularly 
myelosuppression and immunosuppression.14–16 Mela-
tonin has been found to inhibit the production of free 
radicals, which play a part in mediating the   toxicity 
of chemotherapy.14,15 In a pilot study conducted by 
  Lissoni and colleagues,14 80 patients with a variety of 
metastatic solid tumors received chemotherapy with 
or without melatonin 20 mg daily. Thrombocytopenia, 
malaise,  asthenia,  stomatitis,  and  neuropathy  were 
less frequent in patients treated with melatonin. The 
effectiveness of chemotherapy was not altered by the 
addition of melatonin. In another study, 70 patients 
with  non-small  cell  lung  cancer  using  cisplatin 
(20 mg/m2/day intravenously for 3 days) and etopo-
side 100 mg/m2/day for 3 days received melatonin 
20 mg daily or chemotherapy alone. The frequency 
of myelosuppression, neuropathy, and cachexia was 
significantly lower in the melatonin group.15 Inves-
tigators  found  that  the  incidence  of  neuropathy 
with melatonin was 0/34 patients compared to 5/36 
patients who received chemotherapy alone. In addi-
tion there was no impact on the effectiveness of the 
chemotherapy regimen. Tumor response was seen in 
10/34 patients receiving melatonin and 6/36 patients 
receiving chemotherapy alone. The one year survival 
for patients receiving melatonin was 15/34 compared 
to 7/36 in chemotherapy alone patients (p = 0.05). 
Other studies specifically evaluating the myelopro-
tective effect of melatonin when administered with 
chemotherapy failed to show decrease in the inci-
dence of neutropenia.16
Melatonin has been used safely in previous trials 
assessing its use in cancer and other patients.14–16,19–24 
In the two trials by Lissoni and colleagues, there were 
no adverse effects documented that had increased inci-
dence in patients receiving chemotherapy plus mela-
tonin compared to patients receiving chemotherapy 
alone.14,15 The frequency of myelosuppression, neurop-
athy, and cachexia was significantly lower in the mela-
tonin group.15 In our trial, patients receiving melatonin 
during taxane chemotherapy had a reduced incidence 
of all grade neuropathy (46%) compared to historical 
controls (around 60%). We recognize that this study 
included a limited number of patients and lacked the 
power to detect statistically significant differences for 
the various parameters. However, based on the mere 
trend  of  decreased  incidence  of  severe  neuropathy 
and attenuated severity of symptoms, with no major 
changes in FACT-Taxane quality of life, the possibil-
ity that melatonin may be useful in the   prevention or 
reduction of taxane-induced   neuropathy and in main-
taining quality of life seems likely. Larger trials are 
warranted to further explore the role of melatonin in 
taxane-related neuropathy treatment and prevention.
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